Deaths / year
2,000
GBD (indicative unless refreshed)
DALYs / year
180,000
GBD
Pathogen
Helminth
Post-infectious
Chronic disease
Persistent symptoms
n/a
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Post-acute status
Chronic cystic/alveolar organ disease; recurrence after surgery
Classification
Chronic disease
Onset
chronic
Persistent-symptom %
not quantified as a single figure (see notes)
Source: WHO echinococcosis
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Vector & transmission control
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Dog deworming & slaughter hygiene | Vector control | Approved | Break Echinococcus granulosus cycle | WHO |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Albendazole | Anthelmintic | Approved | Microtubule inhibitor; cysticidal adjunct to PAIR/surgery | WHO EML / standard of care |
| Mebendazole | Anthelmintic | Approved | Alternative benzimidazole | WHO EML / standard of care |
| PAIR / surgery | Procedure | Approved | Percutaneous aspiration-injection-reaspiration or resection | WHO EML / standard of care |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Long-term cyst surveillance | Supportive | Approved | Recurrence monitoring after treatment | WHO echinococcosis |
Associated drug targets (Open Targets): IL21, IGHE, PRDX2, LGALS3, IFNG, INS
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0005738 · Updated 2026-07-10. Associations, not a diagnostic test.